TD SYNNEX delivered a strong Q2, exceeding guidance with robust revenue growth, improved margins, and impressive cash ...

Itron remains a Buy as strong cash flow offsets soft FY25 guidance, likely due to delayed backlog, not lost sales. Read why ...

The company said, “Biodexa has experienced net losses and significant cash outflows from cash used in operating activities over the past years as ...

As global markets navigate a complex landscape marked by fluctuating interest rates and economic uncertainties, investors are keenly observing Asia's stock markets for potential opportunities. In this ...